Bolt v. Merrimack Pharmaceuticals, Inc.

503 F.3d 913, 2007 U.S. App. LEXIS 21717, 2007 WL 2597596
CourtCourt of Appeals for the Ninth Circuit
DecidedSeptember 11, 2007
Docket05-16282
StatusPublished
Cited by8 cases

This text of 503 F.3d 913 (Bolt v. Merrimack Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bolt v. Merrimack Pharmaceuticals, Inc., 503 F.3d 913, 2007 U.S. App. LEXIS 21717, 2007 WL 2597596 (9th Cir. 2007).

Opinion

O’SCANNLAIN, Circuit Judge:

We are called upon to interpret a corporation’s articles of organization to decide whether it has an obligation to redeem certain shares of its stock.

I

Albert D. Bolt owns 52,488 shares of Series A Redeemable Preferred Stock (“Series A Stock”) issued by Merrimack Pharmaceuticals, Inc. (“Merrimack”), a biotechnology company organized under the laws of Massachusetts. Bolt now wants to redeem those shares.

The relevant redemption provision of Merrimack’s Restated Articles of Organization provides:

At any time from and after December 31,1997, if the net worth of the Corporation, determined in accordance with generally accepted accounting principles and as shown on the balance sheet of the Corporation as of the end of the fiscal quarter then most recently ended, equals or exceeds five million dollars ($5,000,000.00), then upon the request of the holder of [the Series A] Preferred Stock, the Corporation shall redeem at the Redemption Price any and all shares of [the Series A] Preferred Stock which such holder, by such request, offers to the Corporation for redemption.

The following statement provides a snapshot of Merrimack’s balance sheet as of December 31, 2001:

*915 Assets
Total assets $11,331,070
Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Deficit
Total liabilities $ 1,270,230
Redeemable convertible preferred stock:
Series A redeemable preferred stock $ 548,380
Series B convertible preferred stock $11,915,267
Total redeemable convertible preferred stock $12,463,647
Total stockholders’ deficit ($ 2,402,807) 1
Total liabilities, redeemable convertible preferred stock, and stockholders’ deficit $11,331,070

PricewaterhouseCoopers LLP audited Merrimack’s financial statements, and opined that Merrimack’s balance sheet referred to above “presents fairly, in all material respects, the financial position of Merrimack Pharmaceuticals, Inc. at December 31, 2001 in conformity with accounting principles generally accepted in the United States of America.”

During 2001, Merrimack had issued 3,315,201 shares of Series B Redeemable Convertible Preferred Stock (“Series B Stock”) with a book value of $11,915,267. The Series B Stock is redeemable at the option of the holder upon a “deemed liquidation,” defined as (1) a merger with another company, after which the Merrimack stockholders would no longer hold a majority of the voting power, or (2) the sale of Merrimack’s business assets. The Series B Stock appears in the “mezzanine” of the balance sheet, between the liabilities section and the stockholders’ deficit (equity) section. See David R. Herwitz & Matthew J. Barrett, Accounting for Lawyers 505 (4th ed.2006) (explaining that the “section between liabilities and equity on the balance sheet” is commonly referred to as the “mezzanine”).

On April 11, 2001, and again on March 28, 2002, Bolt sent written requests to Merrimack for the redemption of his shares of Series A Stock. In a letter dated June 13, 2002, Merrimack rejected Bolt’s demands for redemption. Bolt filed suit in federal district court seeking a declaratory judgment that Merrimack’s net worth exceeded $5 million as of December 31, 2001. On cross-motions for summary judgment, the district court granted summary judgment for Bolt, concluding that Merrimack’s net worth exceeded $5 million as of that date.

Merrimack timely appealed.

II

We are faced with the task of interpreting Merrimack’s Restated Articles of Organization to determine if it indeed has an obligation to redeem the Series A Stock held by Bolt. The dispositive issue, of course, is whether Merrimack’s net worth, determined in accordance with generally accepted accounting principles (“GAAP”) and as shown on the balance sheet, equaled or exceeded $5 million as of December 31, 2001. The district court held that it did. We agree.

A

We must first determine the meaning of the term “net worth,” the threshold yard *916 stick to determine whether Merrimack has an obligation to redeem the Series A Stock as Bolt requests. Merrimack’s Restated Articles of Organization fail to define that term. Nor does GAAP define that term. And no item on Merrimack’s balance sheet is specifically labeled “net worth.”

Merrimack is organized under Massachusetts law, and therefore we apply that state’s body of law here. See Order of United Commercial Travelers of Am. v. Wolfe, 331 U.S. 586, 614, 67 S.Ct. 1355, 91 L.Ed. 1687 (1947). Moreover, because articles of organization are contractual in nature, see Willson v. Laconia Car Co., 275 Mass. 435, 176 N.E. 182, 184 (1931), we look to Massachusetts general contract principles. “Where the language of a contract is not ambiguous,” we are instructed to give words “their plain meaning, or their well established meaning.” City of Haverhill v. George Brox, Inc., 47 Mass. App.Ct. 717, 716 N.E.2d 138, 141 (1999) (internal citations omitted); see also Erhard v. F.W. Woolworth Co., 374 Mass. 352, 372 N.E.2d 1277, 1279 (1978); Freelander v. G. & K. Realty Corp., 357 Mass. 512, 258 N.E.2d 786, 788 (1970); Restatement (Second) of Contracts § 202(3) (1981).

The common and well-established meaning of the term “net worth” is the difference between a corporation’s total assets and its total liabilities. 2 Merrimack’s total assets and total liabilities, as shown on its December 31, 2001 balance sheet, equal $11,331,070 and $1,270,230, respectively. Accordingly, employing the well-established meaning, Merrimack’s net worth equals $10,060,840, well in excess of the $5 million threshold set by the Restated Articles of Organization.

Merrimack suggests that net worth is sometimes referred to as stockholders’ equity. 3 This reference is often accurate because a balance sheet generally involves only three basic accounting elements-assets, liabilities, and equity-and equity by definition equals the residual interest in the assets after subtracting liabilities. 4 Yet, under this reasoning, Merrimack’s net worth would still exceed $5 million.

But Merrimack goes further, arguing that the definition of net worth for purposes of its Restated Articles of Organization equals

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Masih v. Perrigo Company PLC
S.D. New York, 2020
Gate Guard Services L.P. v. Perez
14 F. Supp. 3d 825 (S.D. Texas, 2014)
C. Brewer & Co. v. Hawaii Insurance Guaranty Ass'n
231 P.3d 60 (Hawaii Intermediate Court of Appeals, 2010)
In Re Moneygram International, Inc. Securities Litigation
626 F. Supp. 2d 947 (D. Minnesota, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
503 F.3d 913, 2007 U.S. App. LEXIS 21717, 2007 WL 2597596, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bolt-v-merrimack-pharmaceuticals-inc-ca9-2007.